Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
06 2021
Historique:
received: 24 12 2020
revised: 19 02 2021
accepted: 17 03 2021
pubmed: 11 4 2021
medline: 29 6 2021
entrez: 10 4 2021
Statut: ppublish

Résumé

To identify the effect of single nucleotide polymorphism (SNP) interactions on the risk of toxicity following radiotherapy (RT) for prostate cancer (PCa) and propose a new method for polygenic risk score incorporating SNP-SNP interactions (PRSi). Analysis included the REQUITE PCa cohort that received external beam RT and was followed for 2 years. Late toxicity endpoints were: rectal bleeding, urinary frequency, haematuria, nocturia, decreased urinary stream. Among 43 literature-identified SNPs, the 30% most strongly associated with each toxicity were tested. SNP-SNP combinations (named SNP-allele sets) seen in ≥10% of the cohort were condensed into risk (RS) and protection (PS) scores, respectively indicating increased or decreased toxicity risk. Performance of RS and PS was evaluated by logistic regression. RS and PS were then combined into a single PRSi evaluated by area under the receiver operating characteristic curve (AUC). Among 1,387 analysed patients, toxicity rates were 11.7% (rectal bleeding), 4.0% (urinary frequency), 5.5% (haematuria), 7.8% (nocturia) and 17.1% (decreased urinary stream). RS and PS combined 8 to 15 different SNP-allele sets, depending on the toxicity endpoint. Distributions of PRSi differed significantly in patients with/without toxicity with AUCs ranging from 0.61 to 0.78. PRSi was better than the classical summed PRS, particularly for the urinary frequency, haematuria and decreased urinary stream endpoints. Our method incorporates SNP-SNP interactions when calculating PRS for radiotherapy toxicity. Our approach is better than classical summation in discriminating patients with toxicity and should enable incorporating genetic information to improve normal tissue complication probability models.

Identifiants

pubmed: 33838170
pii: S0167-8140(21)06161-2
doi: 10.1016/j.radonc.2021.03.024
pmc: PMC8754257
mid: NIHMS1767939
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

241-248

Subventions

Organisme : NCI NIH HHS
ID : K07 CA187546
Pays : United States

Investigateurs

Yolande Lievens (Y)
Marc van Eijkeren (M)
Christel Monten (C)
Wilfried De Neve (W)
Stephanie Peeters (S)
Caroline Weltens (C)
Gilles Defraene (G)
Erik van Limberghen (E)
Erik Briers (E)
Celine Bourgier (C)
Roxana Draghici (R)
Francoise Bons (F)
Thomas Blaschke (T)
Christian Weiß (C)
Irmgard Helmbold (I)
Christian Weißenberger (C)
Petra Stegmaier (P)
Johannes Claßen (J)
Ulrich Giesche (U)
Marie-Luise Sautter-Bihl (ML)
Burkhard Neu (B)
Thomas Schnabel (T)
Michael Ehmann (M)
Benjamin Gauter-Fleckenstein (B)
Jörg Schäfer (J)
Tommaso Giandini (T)
Marzia Franceschini (M)
Claudia Sangalli (C)
Sara Morlino (S)
Laura Lozza (L)
Maria C De Santis (MC)
Gabriele Pietro (G)
Elena Delmastro (E)
Elisabetta Garibaldi (E)
Alessandro Cicchetti (A)
Bibiana Piqué-Leiva (B)
Meritxel Molla (M)
Alexandra Giraldo (A)
Monica Ramos (M)
Ramon Lobato-Busto (R)
Laura Torrado Moya (L)
Isabel Dominguez-Rios (I)
Irene Fajardo-Paneque (I)
Patricia Calvo-Crespo (P)
Ana Carballo (A)
Paula Peleteiro (P)
None Olivia-Fuentes-Rios
Antonio Gomez-Caamano (A)
Victoria Harrop (V)
Debbie Payne (D)
Manjusha Keni (M)
Paul R Symonds (PR)
Samuel Lavers (S)
Simon Wright (S)
Sridhar Thiagarajan (S)
Luis Aznar-Garcia (L)
Kiran Kancherla (K)
Christopher Kent (C)
Subramaniam Vasanthan (S)
Donna Appleton (D)
Monika Kaushik (M)
Frances Kenny (F)
Hazem Khout (H)
Jaroslaw Krupa (J)
Kelly V Lambert (KV)
Simon Pilgrim (S)
Sheila Shokuhi (S)
Kalliope Valassiadou (K)
Ion Bioangiu (I)
Kufre Sampson (K)
Ahmed Osman (A)
Corinne Faivre-Finn (C)
Karen Foweraker (K)
Abigail Pascoe (A)
Claire P Esler (CP)
Tim Ward (T)
Daniel S Higginson (DS)
Sheryl Green (S)

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Acta Oncol. 2018 Nov;57(11):1499-1505
pubmed: 29952681
Clin Oncol (R Coll Radiol). 2014 Dec;26(12):739-42
pubmed: 25267305
G3 (Bethesda). 2016 Jul 07;6(7):2043-50
pubmed: 27185397
Front Oncol. 2020 Oct 15;10:541281
pubmed: 33178576
Front Oncol. 2017 Apr 27;7:83
pubmed: 28497027
Hum Mol Genet. 2019 Nov 21;28(R2):R143-R150
pubmed: 31504522
Brief Funct Genomics. 2015 Mar;14(2):143-55
pubmed: 25241224
J Natl Cancer Inst. 2020 Feb 1;112(2):179-190
pubmed: 31095341
Front Oncol. 2018 Jun 21;8:228
pubmed: 29977864
BMC Cancer. 2006 May 03;6:114
pubmed: 16672066
Bioinformatics. 2015 May 1;31(9):1466-8
pubmed: 25550326
Radiother Oncol. 2019 Sep;138:59-67
pubmed: 31146072
Cardiovasc Drugs Ther. 2021 Jun;35(3):627-635
pubmed: 33156471
Trends Genet. 2013 Dec;29(12):669-76
pubmed: 24161664
PLoS Genet. 2013 Mar;9(3):e1003348
pubmed: 23555274
Circ Cardiovasc Genet. 2010 Oct;3(5):468-74
pubmed: 20729558
Radiother Oncol. 2017 Oct;125(1):107-112
pubmed: 28823404
Hum Mol Genet. 2002 Oct 1;11(20):2463-8
pubmed: 12351582
BMC Med Genet. 2017 Oct 3;18(1):107
pubmed: 28974197
Nat Genet. 2018 Sep;50(9):1219-1224
pubmed: 30104762
Hum Hered. 2003;56(1-3):73-82
pubmed: 14614241
Sci Rep. 2017 Feb 24;7:43381
pubmed: 28233873

Auteurs

Nicola Rares Franco (NR)

MOX, Department of Mathematics, Politecnico di Milano, Italy. Electronic address: nicolarares.franco@polimi.it.

Michela Carlotta Massi (MC)

MOX, Department of Mathematics, Politecnico di Milano, Italy; CADS-Center for Analysis, Decisions and Society, Human Technopole, Milan, Italy. Electronic address: michelacarlotta.massi@polimi.it.

Francesca Ieva (F)

MOX, Department of Mathematics, Politecnico di Milano, Italy; CADS-Center for Analysis, Decisions and Society, Human Technopole, Milan, Italy; CHRP-National Center for Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, Milan, Italy. Electronic address: francesca.ieva@polimi.it.

Andrea Manzoni (A)

MOX, Department of Mathematics, Politecnico di Milano, Italy. Electronic address: andrea1.manzoni@polimi.it.

Anna Maria Paganoni (AM)

MOX, Department of Mathematics, Politecnico di Milano, Italy; CADS-Center for Analysis, Decisions and Society, Human Technopole, Milan, Italy; CHRP-National Center for Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, Milan, Italy. Electronic address: anna.paganoni@polimi.it.

Paolo Zunino (P)

MOX, Department of Mathematics, Politecnico di Milano, Italy. Electronic address: paolo.zunino@polimi.it.

Liv Veldeman (L)

Department of Human Structure and Repair, Ghent University, Belgium; Department of Radiation Oncology, Ghent University Hospital, Belgium. Electronic address: liv.veldeman@ugent.be.

Piet Ost (P)

Department of Human Structure and Repair, Ghent University, Belgium; Department of Radiation Oncology, Ghent University Hospital, Belgium. Electronic address: piet.ost@ugent.be.

Valérie Fonteyne (V)

Department of Human Structure and Repair, Ghent University, Belgium; Department of Radiation Oncology, Ghent University Hospital, Belgium. Electronic address: valerie.fonteyne@uzgent.be.

Christopher J Talbot (CJ)

Leicester Cancer Research Centre, Department of Genetics and Genome Biology, University of Leicester, United Kingdom. Electronic address: cjt14@leicester.ac.uk.

Tim Rattay (T)

Leicester Cancer Research Centre, Department of Genetics and Genome Biology, University of Leicester, United Kingdom. Electronic address: tr104@leicester.ac.uk.

Adam Webb (A)

Leicester Cancer Research Centre, Department of Genetics and Genome Biology, University of Leicester, United Kingdom. Electronic address: ajw51@leicester.ac.uk.

Kerstie Johnson (K)

Leicester Cancer Research Centre, Department of Genetics and Genome Biology, University of Leicester, United Kingdom. Electronic address: kj91@leicester.ac.uk.

Maarten Lambrecht (M)

Department of Radiation Oncology, University Hospitals Leuven, Belgium. Electronic address: maarten.lambrecht@uzleuven.be.

Karin Haustermans (K)

Department of Radiation Oncology, University Hospitals Leuven, Belgium. Electronic address: karin.haustermans@uzleuven.be.

Gert De Meerleer (G)

Department of Radiation Oncology, University Hospitals Leuven, Belgium. Electronic address: gert.demeerleer@uzleuven.be.

Dirk de Ruysscher (D)

Maastricht University Medical Center, the Netherlands; Department of Radiation Oncology (Maastro), GROW Institute for Oncology and Developmental Biology, Maastricht, the Netherlands. Electronic address: dirk.deruysscher@maastro.nl.

Ben Vanneste (B)

Department of Radiation Oncology (Maastro), GROW Institute for Oncology and Developmental Biology, Maastricht, the Netherlands. Electronic address: ben.vanneste@maastro.nl.

Evert Van Limbergen (E)

Maastricht University Medical Center, the Netherlands; Department of Radiation Oncology (Maastro), GROW Institute for Oncology and Developmental Biology, Maastricht, the Netherlands. Electronic address: evert.vanlimbergen@maastro.nl.

Ananya Choudhury (A)

Translational Radiobiology Group, Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, UK. Electronic address: ananya.choudhury@nhs.net.

Rebecca M Elliott (RM)

Translational Radiobiology Group, Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, UK. Electronic address: rebecca.m.elliott@manchester.ac.uk.

Elena Sperk (E)

Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Germany. Electronic address: Elena.sperk@umm.de.

Marlon R Veldwijk (MR)

Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Germany. Electronic address: marlon.veldwijk@medma.uni-heidelberg.de.

Carsten Herskind (C)

Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Germany. Electronic address: Carsten.herskind@medma.uni-heidelberg.de.

Barbara Avuzzi (B)

Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: barbara.avuzzi@istitutotumori.mi.it.

Barbara Noris Chiorda (B)

Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: Barbara.Noris@istitutotumori.mi.it.

Riccardo Valdagni (R)

Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, Milan, Italy; Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: riccardo.valdagni@istitutotumori.mi.it.

David Azria (D)

Department of Radiation Oncology, University Federation of Radiation Oncology, Montpellier Cancer Institute, Univ Montpellier MUSE, France. Electronic address: David.Azria@icm.unicancer.fr.

Marie-Pierre Farcy-Jacquet (MP)

Department of Radiation Oncology, University Federation of Radiation Oncology, Institut de Cancérologie du Gard, Nimes, France. Electronic address: marie.pierre.farcy.jacquet@chu-nimes.fr.

Muriel Brengues (M)

Department of Radiation Oncology, University Federation of Radiation Oncology, Montpellier Cancer Institute, Univ Montpellier MUSE, France. Electronic address: muriel.brengues@icm.unicancer.fr.

Barry S Rosenstein (BS)

Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, USA. Electronic address: Barry.Rosenstein@mssm.edu.

Richard G Stock (RG)

Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, USA. Electronic address: richard.stock@mssm.edu.

Ana Vega (A)

Grupo de Medicina Xenómica (USC), Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela, Spain; Biomedical Network on Rare Diseases (CIBERER), Spain. Electronic address: ana.vega@usc.es.

Miguel E Aguado-Barrera (ME)

Grupo de Medicina Xenómica (USC), Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela, Spain. Electronic address: miguelelias.aguado@usc.es.

Paloma Sosa-Fajardo (P)

Grupo de Medicina Xenómica (USC), Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela, Spain; Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain. Electronic address: paloma.sosa.fajardo@sergas.es.

Alison M Dunning (AM)

Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Labs, UK. Electronic address: amd24@medschl.cam.ac.uk.

Laura Fachal (L)

Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Labs, UK; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK. Electronic address: lf370@medschl.cam.ac.uk.

Sarah L Kerns (SL)

Departments of Radiation Oncology and Surgery, University of Rochester Medical Center, Rochester, USA. Electronic address: Sarah_Kerns@URMC.Rochester.edu.

Debbie Payne (D)

Centre for Integrated Genomic Medical Research (CIGMR), University of Manchester, UK. Electronic address: Debbie.Payne@manchester.ac.uk.

Jenny Chang-Claude (J)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Germany. Electronic address: j.chang-claude@dkfz-heidelberg.de.

Petra Seibold (P)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: p.seibold@Dkfz-Heidelberg.de.

Catharine M L West (CML)

Translational Radiobiology Group, Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, UK. Electronic address: Catharine.West@manchester.ac.uk.

Tiziana Rancati (T)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: Tiziana.rancati@istitutotumori.mi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH